Brucke Financial Inc. bought a new position in Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 6,121 shares of the company's stock, valued at approximately $641,000.
Other large investors have also recently added to or reduced their stakes in the company. Continuum Advisory LLC increased its stake in Novartis by 10.3% in the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company's stock valued at $99,000 after acquiring an additional 95 shares during the period. Bryn Mawr Capital Management LLC boosted its holdings in Novartis by 0.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock valued at $1,254,000 after purchasing an additional 100 shares in the last quarter. Rothschild Investment LLC grew its stake in shares of Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock valued at $1,623,000 after purchasing an additional 101 shares during the period. Meridian Wealth Management LLC grew its stake in shares of Novartis by 2.6% in the 4th quarter. Meridian Wealth Management LLC now owns 4,161 shares of the company's stock valued at $405,000 after purchasing an additional 106 shares during the period. Finally, Angeles Wealth Management LLC raised its holdings in shares of Novartis by 3.5% in the 4th quarter. Angeles Wealth Management LLC now owns 3,249 shares of the company's stock worth $316,000 after buying an additional 110 shares in the last quarter. Institutional investors own 13.12% of the company's stock.
Novartis Price Performance
Shares of NVS stock traded up $3.09 during trading hours on Friday, reaching $115.67. 2,448,684 shares of the company were exchanged, compared to its average volume of 2,178,936. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $120.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.84. The stock's fifty day moving average is $109.91 and its two-hundred day moving average is $106.01. The company has a market cap of $244.34 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.70 and a beta of 0.60.
Novartis (NYSE:NVS - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.16. The firm had revenue of $13.23 billion during the quarter, compared to analysts' expectations of $12.92 billion. Novartis had a net margin of 23.56% and a return on equity of 37.24%. Novartis's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.80 EPS. Sell-side analysts forecast that Novartis AG will post 8.45 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts recently commented on the company. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. UBS Group restated a "neutral" rating on shares of Novartis in a research note on Thursday, February 13th. Wall Street Zen upgraded shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Finally, BNP Paribas raised shares of Novartis to a "strong-buy" rating in a research note on Tuesday, April 15th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $123.38.
Check Out Our Latest Analysis on NVS
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
